Remove Diabetes Remove Immunization Remove Pharmaceutical Companies
article thumbnail

Advancing microbiome innovation

European Pharmaceutical Review

While this approach has shown to be safe and efficient in Clostridium difficile, the variability between donors may lead to random outcomes and responses in patients for immune-mediated diseases. Internet] Pharmaceutical Technology. Notably, from one donor to another, significant variations exist.

article thumbnail

Developing a first-in-class small molecule drug for inflammatory disease

European Pharmaceutical Review

TNF-alpha is an immune modulating cytokine whose dysregulation can lead to prolonged inflammatory responses and is known to drive disease in a range of autoimmune and inflammatory disorders. MYMD-1 has shown effectiveness in pre-clinical and clinical studies in regulating the immune system.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

AI’s infiltration of pharma: How COVID-19 accelerated change

pharmaphorum

Predicting protein structures would typically be a time-consuming process, but now scientists can use technology to better analyse viruses, thus helping in the search for a vaccine that can trigger an immune response. Scientists are using AI to sift through existing literature on a disease and study its disease’s structure.

Vaccines 132
article thumbnail

Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Retatrutide?

Pharmaceutical Technology

Retatrutide Overview Retatrutide (LY-3437943) is under development for the treatment of type 2 diabetes mellitus and obesity. Eli Lilly and Co Overview Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products.

article thumbnail

MP-0310 by Molecular Partners for Cervical Cancer: Likelihood of Approval

Pharmaceutical Technology

Molecular Partners overview Molecular Partners is a clinical-stage bio-pharmaceutical company that develops biological drugs. The company offers advanced small protein therapies such as abicipar, a designed ankyrin repeat protein-based anti-angiogenic drug developed for diabetic macular edema and wet age- macular degeneration.

article thumbnail

MP-0310 by Molecular Partners for Colorectal Cancer: Likelihood of Approval

Pharmaceutical Technology

Molecular Partners overview Molecular Partners is a clinical-stage bio-pharmaceutical company that develops biological drugs. The company offers advanced small protein therapies such as abicipar, a designed ankyrin repeat protein-based anti-angiogenic drug developed for diabetic macular edema and wet age- macular degeneration.

article thumbnail

Leading innovators in pancreatic extract-based compositions for the pharmaceutical industry

Pharmaceutical Technology

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.